Project

Development of next-generation combination therapy of Alzheimer’s disease

Project Summary

To overcome limited therapeutic efficacy of Alzheimer's disease, combination therapy targeting multiple molecules is necessary and our R&D objectives are described below
- Evaluation and candidate selection of Alzheimer drugs for cognitive recovery including Donepezil
- Evaluation of combinatory effects with AS-P101 (disease-modifying drug) in Alzheimer's disease model
- Final candidate selection of next-generation combination therapeutics and study on mode-of-action and its optimization

Business Model

- Revenue Model: Global licensing-out in early stage with Big Pharma
- Target Customer: Global Big Pharma
- Overseas Accomplishment: Collaborate with candidates of Big Pharma capable of global lisencing-out from the early stage of development and trasfer technology at an early stage (preclinical ~ Phase 1)

Main Achievements

- Follow-up Investment: Planned in the 1Q of 2018
- Employment: 4 → 10 by the end of 2019
- Dissertations or IP: Applied patent Kor (1)